Profile data is unavailable for this security.
About the company
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
- Revenue in USD (TTM)226.00k
- Net income in USD-18.16m
- Incorporated1998
- Employees16.00
- LocationTraws Pharma Inc12 Penns TrailNEWTOWN 18940United StatesUSA
- Phone+1 (267) 759-3680
- Fax+1 (267) 759-3681
- Websitehttps://www.onconova.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imunon Inc | 0.00 | -18.85m | 13.54m | 33.00 | -- | 1.59 | -- | -- | -2.02 | -2.02 | 0.00 | 0.9041 | 0.00 | -- | -- | 0.00 | -66.82 | -50.18 | -91.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Akari Therapeutics PLC (ADR) | -100.00bn | -100.00bn | 13.58m | 9.00 | -- | -- | -- | -- | -- | -- | -- | -0.4449 | -- | -- | -- | -- | -- | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Senti Biosciences Inc | 1.28m | -86.11m | 13.73m | 48.00 | -- | 0.2445 | -- | 10.77 | -1.93 | -1.44 | 0.0285 | 1.23 | 0.0097 | -- | 2.94 | 26,562.50 | -65.33 | -- | -71.42 | -- | -- | -- | -6,753.80 | -- | -- | -- | 0.0018 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -7.25m | 13.93m | 16.00 | -- | 3.22 | -- | -- | -2.37 | -2.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -84.50 | -- | -107.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 14.01m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.08m | 14.24m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
| Microbot Medical Inc | 0.00 | -10.26m | 14.40m | 22.00 | -- | 2.33 | -- | -- | -0.8926 | -0.8926 | 0.00 | 0.4283 | 0.00 | -- | -- | 0.00 | -151.13 | -53.28 | -183.85 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| Traws Pharma Inc | 226.00k | -18.16m | 14.52m | 16.00 | -- | 2.01 | -- | 64.26 | -0.8641 | -0.8641 | 0.0108 | 0.2853 | 0.0085 | -- | 12.91 | 14,125.00 | -68.21 | -63.43 | -104.99 | -85.72 | -- | -- | -8,033.63 | -3,257.92 | -- | -- | 0.00 | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Mannatech Inc | 127.23m | -1.66m | 14.60m | 213.00 | -- | 1.40 | -- | 0.1147 | -0.899 | -0.899 | 68.07 | 5.54 | 2.77 | 1.93 | 561.74 | 597,342.80 | -3.62 | 4.39 | -9.67 | 9.16 | 78.01 | 77.87 | -1.31 | 1.72 | 0.5584 | -- | 0.1384 | 88.33 | -3.83 | -5.33 | 50.13 | -- | -20.38 | -- |
| Flora Growth Corp | 74.78m | -47.58m | 14.74m | 97.00 | -- | 3.29 | -- | 0.1971 | -6.53 | -7.77 | 9.20 | 0.3494 | 1.48 | 5.99 | 23.05 | 770,958.80 | -92.50 | -- | -140.01 | -- | 21.72 | -- | -62.66 | -- | 0.6481 | -- | 0.4952 | -- | 127.75 | -- | -1.87 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 70.00k | -7.79m | 14.83m | 22.00 | -- | 1.25 | -- | 211.83 | -0.0197 | -0.0197 | 0.0002 | 0.0296 | 0.0021 | -- | 3.61 | 3,181.82 | -24.46 | -25.03 | -49.25 | -48.76 | -- | -- | -11,536.00 | -1,692.93 | -- | -0.4696 | 0.5341 | -- | -- | -- | -255.12 | -- | -- | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.17m | 15.10m | 3.00 | -- | 3.25 | -- | -- | -0.0184 | -0.0184 | 0.00 | 0.0269 | 0.00 | -- | -- | 0.00 | -34.05 | 27.48 | -34.48 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -19.34m | 15.21m | 20.00 | -- | -- | -- | -- | -26.80 | -26.80 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -72.94 | -- | -92.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 12.39 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Traws Pharma Inc's reporting currency: US Dollar USD
10.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| OrbiMed Advisors LLCas of 01 Apr 2024 | 1.05m | 4.13% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 702.07k | 2.78% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 268.19k | 1.06% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 248.88k | 0.98% |
| Geode Capital Management LLCas of 31 Mar 2024 | 192.86k | 0.76% |
| Two Sigma Advisers LPas of 31 Mar 2024 | 73.07k | 0.29% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 52.79k | 0.21% |
| Two Sigma Investments LPas of 31 Mar 2024 | 37.99k | 0.15% |
| Citadel Securities LLCas of 31 Mar 2024 | 36.82k | 0.15% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 30.78k | 0.12% |
More ▼
Data from 31 Mar 2024 - 01 Apr 2024Source: FactSet Research Systems Inc.
